International Journal of Cardiology
Volume 103, Issue 3 , Pages 298-306 , 1 September 2005

Oxidized LDL inhibit hepatocyte growth factor synthesis in coronary smooth muscle cells

Received 12 May 2004 ,Accepted 13 August 2004.

References 

  1. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun. 1984;122:1450–1459
  2. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440–443
  3. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119:629–641
  4. Kawaida K, Matsumoto K, Shimazu H, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci U S A. 1994;91:4357–4361
  5. Park M, Dean M, Kaul K, Braun MJ, Gonda MA, Vande Woude G. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc Natl Acad Sci U S A. 1987;84:6379–6383
  6. Yo Y, Morishita R, Yamamoto K, Tomita N, Kida I, Hayashi S, et al. Actions of hepatocyte growth factor as a local modulator in the kidney: potential role in pathogenesis of renal disease. Kidney Int. 1998;53:50–58
  7. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251:802–804
  8. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature. 1989;339:155–156
  9. Morishita R, Nakamura S, Hayashi S, Taniyama Y, Moriguchi A, Nagano T, et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension. 1999;33:1379–1384
  10. Hayashi K, Nakamura S, Morishita R, Moriguchi A, Aoki M, Matsumoto K, et al. In vivo transfer of human hepatocyte growth factor gene accelerates re-endothelialization and inhibits neointimal formation after balloon injury in rat model. Gene Ther. 2000;7:1664–1671
  11. Ma H, Calderon TM, Kessel T, Ashton AW, Berman JW. Mechanisms of hepatocyte growth factor-mediated vascular smooth muscle cell migration. Circ Res. 2003;93:1066–1073
  12. Taher TE, Derksen PW, de Boer OJ, Spaargaren M, Teeling P, van der Wal AC, et al. Hepatocyte growth factor triggers signaling cascades mediating vascular smooth muscle cell migration. Biochem Biophys Res Commun. 2002;298:80–86
  13. Walter JJ, Sane DC. Angiostatin binds to smooth muscle cells in the coronary artery and inhibits smooth muscle cell proliferation and migration in vitro. Arterioscler Thromb Vasc Biol. 1999;19:2041–2048
  14. Laping NJ, Olson BA, Ho T, Ziyadeh FN, Albrightson CR. Hepatocyte growth factor: a regulator of extracellular matrix genes in mouse mesangial cells. Biochem Pharmacol. 2000;59:847–853
  15. Liu Y, Centracchio JN, Lin L, Sun AM, Dworkin LD. Constitutive expression of HGF modulates renal epithelial cell phenotype and induces c-met and fibronectin expression. Exp Cell Res. 1998;242:174–185
  16. Hamasuna R, Kataoka H, Moriyama T, Itoh H, Seiki M, Koono M. Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP. Int J Cancer. 1999;82:274–281
  17. Hanzawa M, Shindoh M, Higashino F, Yasuda M, Inoue N, Hida K, et al. Hepatocyte growth fractor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis. 2000;21:1079–1085
  18. Liu Y, Rajur K, Tolbert E, Dworkin LD. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int. 2000;58:2028–2043
  19. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model. Circulation. 2001;104:2344–2350
  20. Cominacini L, Garbin U, Davoli A, Micciolo R, Bosello O, Gaviraghi G, et al. A simple test for predisposition to LDL oxidation based on the fluorescence development during copper-catalyzed oxidative modification. J Lipid Res. 1991;32:349–358
  21. Labarca C, Paigen K. A simple, rapid and sensitive DNA assay procedure. Anal Biochem. 1980;102:344–352
  22. Nakajima-Iijima S, Hamada H, Reddy P, Kakunaga T. Molecular structure of the human cytoplasmic β-actin gene: interspecies homology of sequences in the introns. Proc Natl Acad Sci U S A. 1985;82:6133–6137
  23. Bachem MG, Schneider E, Gross H, Weidenbach H, Schmid RM, Menke A, et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology. 1998;115:421–432
  24. Haug C, Schmid-Kotsas A, Zorn U, Bachem MG, Schuett S, Gruenert A, et al. Hepatocyte growth factor is upregulated by low-density lipoproteins and inhibits endothelin-1 release. Am J Physiol. 2000;279:H2865–H2871
  25. Ma H, Calderon TM, Fallon JT, Berman JW. Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques. Atherosclerosis. 2002;164:79–87
  26. Morishita R, Higaki J, Hayashi SI, Yo Y, Aoki M, Nakamura S, et al. Role of hepatocyte growth factor in endothelial regulation: prevention of high d-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor. Diabetologia. 1997;40:1053–1061
  27. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, Yamasaki K, et al. Hepatocyte growth factor prevents endothelial cell death through inhibition of bax translocation from cytosol to mitochondrial membrane. Diabetes. 2002;51:2604–2611
  28. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A, et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens. 1996;14:1067–1072
  29. Nakamura Y, Morishita R, Nakamura S, Aoki M, Moriguchi A, Matsumoto K, et al. A vascular modulator, hepatocyte growth factor, is associated with systolic pressure. Hypertension. 1996;28:409–413
  30. Morishita R, Nakamura S, Nakamura Y, Aoki M, Moriguchi A, Kida I, et al. Potential role of an endothelium-specific growth factor, hepatocyte growth factor, on endothelial damage in diabetes. Diabetes. 1997;46:138–142
  31. Matsumoto S, Kobayashi T, Katoh M, Saito S, Ikeda Y, Kobori M, et al. Expression and localization of matrix metalloproteinase-12 in the aorta of cholesterol-fed rabbits. Relationship to lesion development. Am J Pathol. 1998;153:109–119
  32. Schönbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40–CD40 ligand signaling in vitro and in vivo. J Exp Med. 1999;189:843–853
  33. Uzui H, Harpf A, Liu M, Doherty TM, Shukla A, Chai NN, et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque. Role of activated macrophages and inflammatory cytokines. Circulation. 2002;106:3024–3030
  34. Huang Y, Mironova M, Lopes-Virella MF. Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19:2640–2647
  35. Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques. Evidence for activation by proinflammatory mediators. Circulation. 1999;99:3103–3109
  36. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem. 1999;274:11924–11929
  37. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation. 1999;99:993–998
  38. Cheng L, Mantile G, Pauly R, Nater C, Felici A, Monticone R, et al. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation. 1998;98:2195–2201
  39. Cho A, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res. 2002;91:845–851
  40. Mason DP, Kenagy RD, Hasenstab D, Bowen-Pope DF, Seifert RA, Coats S, et al. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ Res. 1999;85:1179–1185
  41. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995;92:1565–1569
  42. Wang H, Keiser JA. Hepatocyte growth factor enhances MMP activity in human endothelial cells. Biochem Biophys Res Commun. 2000;272:900–905
  43. Li R, Huang L, Guo H, Toole BP. Basigin (murine EMMPRIN) stimulates matrix metalloproteinase production by fibroblasts. J Cell Physiol. 2001;186:371–379
  44. Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 2001;61:2276–2281
  45. Choi EY, Kim D, Hong BK, Kwon HM, Song YG, Byun KH, et al. Upregulation of extracellular matrix metalloproteinase inducer (EMMPRIN) and gelatinases in human atherosclerosis infected with Chlamydia pneumoniae: the potential role of Chlamydia pneumoniae infection in the progression of atherosclerosis. Exp Mol Med. 2002;34:391–400
  46. Major TC, Liang L, Lu X, Rosebury W, Bocan TMA. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol. 2002;22:1200–1207
  47. Haug C, Lenz C, Díaz F, Bachem MG. Oxidized low-density lipoproteins stimulate extracellular matrix metalloproteinase inducer (EMMPRIN) release by coronary smooth muscle cells. Arterioscler Thromb Vasc Biol. 2004;24:1823–1829

☆ This work was supported by a grant from Deutsche Forschungsgemeinschaft (SFB 451, Teilprojekt B3 to Cornelia Haug and Max Georg Bachem).

PII: S0167-5273(05)00055-0

doi: 10.1016/j.ijcard.2004.08.059

International Journal of Cardiology
Volume 103, Issue 3 , Pages 298-306 , 1 September 2005

Article Tools

* Image Usage & Resolution